Sustained virologic response in CKD patients with hepatitis C: Evidence from Elbasvir/Grazoprevir treatment in Sebha, Libya

Background: Hepatitis C virus (HCV) affects an estimated 58 million people globally, with chronic kidney disease (CKD) patients at higher risk due to shared risk factors and impaired drug metabolism. Direct-acting antivirals (DAAs), like Elbasvir/Grazoprevir, offer promising treatment options, though limited data exists in resource-limited settings. The study aims to assess the efficacy and safety of Elbasvir/Grazoprevir in treating HCV in CKD Stage 5 patients in Sebha, Libya, focusing on real-world applicability in low-resource environments. Methods: A retrospective cohort study was conducted at Sebha Medical Center involving 19 CKD Stage 5 patients treated with Elbasvir/Grazoprevir (12-week regimen). The primary endpoint was sustained virologic response 12 weeks post-treatment (SVR12). Safety was assessed by monitoring adverse events. All patients (100%) achieved SVR12. Baseline viral load ranged from 19.7 to 23.2 IU/mL. Results: No adverse events or discontinuations were reported, and liver function tests remained normal. A weak, non-significant negative correlation was found between age and baseline viral load (r = -0.185), but this did not impact treatment outcomes. Elbasvir/Grazoprevir is highly effective and well-tolerated in CKD Stage 5 patients with HCV in Sebha, Libya, achieving a 100% SVR12 rate. Conclusion: This treatment shows promise in resource-constrained settings, but more extensive studies are needed to confirm these findings.